Effects of age, sex, cardiovascular comorbidities, and kidney function on outcomes with oral anticoagulation therapy in patients with device-detected atrial fibrillation. The NOAH-AFNET 6 trial. - discussion

7 April 2024 (08:30 - 15:00)

Organised by:

Sign in for access options

Sign in for access options

About the speaker

Doctor Sana Al-Khatib

Duke University Medical Center, Durham (United States of America)

9 More presentations in this session

Presentation thumbnail

Clinical benefits of the Closed Loop Stimulation in Sinus Node Disease

Doctor E. Pisano (Lecce, IT)

Presentation thumbnail

Clinical benefits of the Closed Loop Stimulation in Sinus Node Disease - discussion

Doctor N. Varma (Cleveland, US)

Presentation thumbnail

Effects of age, sex, cardiovascular comorbidities, and kidney function on outcomes with oral anticoagulation therapy in patients with device-detected atrial fibrillation. The NOAH-AFNET 6 trial.

Doctor J. Nikorowitsch (Hamburg, DE)

Presentation thumbnail

Risk of stroke or systemic embolism according to baseline frequency and duration of subclinical atrial fibrillation: Insights from the ARTESiA trial

Doctor W. McIntyre (Hamilton, CA)

Presentation thumbnail

Risk of stroke or systemic embolism according to baseline frequency and duration of subclinical atrial fibrillation: Insights from the ARTESiA trial - discussion

Professor T. Potpara (Belgrade, RS)

Access the full session

Session thumbnail

Late-Breaking Science: devices

The Event

Event poster

EHRA 2024

7 April - 9 April 2024

You may be interested in

ESC TV Today

Episode 13: Current indications for pulmonary vein isolation - Conduction system pacing

Congress Presentation

ESC Vice-President

Congress Session

General Assembly

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources